Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 200ug;  ;  ;   - powder for inhalation - 200 mcg/dose - active: budesonide 200ug       - bronchial asthma requiring maintenance treatment with glucocorticosteroids for control of the underlying airways inflammation.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 400ug;  ;  ;   - powder for inhalation - 400 mcg/dose - active: budesonide 400ug       - bronchial asthma requiring maintenance treatment with glucocorticosteroids for control of the underlying airways inflammation.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 80ug equivalent to 100 µg metered dose;  ;  ;  ; formoterol fumarate 4.5ug equivalent to 6 µg metered dose;   - powder for inhalation - active: budesonide 80ug equivalent to 100 µg metered dose       formoterol fumarate 4.5ug equivalent to 6 µg metered dose   excipient: lactose monohydrate - symbicort turbuhaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations. symbicort turbuhaler is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 160ug equivalent to 200 µg metered dose;  ;  ;  ; formoterol fumarate 4.5ug equivalent to 6 µg metered dose;   - powder for inhalation - active: budesonide 160ug equivalent to 200 µg metered dose       formoterol fumarate 4.5ug equivalent to 6 µg metered dose   excipient: lactose monohydrate - symbicort turbuhaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations. symbicort turbuhaler is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 320ug equivalent to 400 µg metered dose;  ;  ;  ; formoterol fumarate 9ug equivalent to 12 µg metered dose;   - powder for inhalation - active: budesonide 320ug equivalent to 400 µg metered dose       formoterol fumarate 9ug equivalent to 12 µg metered dose   excipient: lactose monohydrate - symbicort turbuhaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations. symbicort turbuhaler is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 80ug;  ;  ;  ; formoterol fumarate 4.5ug;   - aerosol inhaler, metered dose - 100/6 - active: budesonide 80ug       formoterol fumarate 4.5ug   excipient: apaflurane macrogol 1000 povidone - symbicort rapihaler 100/6 is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate. this includes: · patients who are not adequately controlled with inhaled corticosteroid therapy and ?as needed? inhaled short-acting beta-2 adrenoceptor agonists. · patients who are already adequately controlled on regular separate long acting beta-agonist and inhaled corticosteroid therapies.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - budesonide 160ug;  ;  ;  ; formoterol fumarate 4.5ug;   - aerosol inhaler, metered dose - 200/6 - active: budesonide 160ug       formoterol fumarate 4.5ug   excipient: apaflurane macrogol 1000 povidone - symbicort rapihaler 100/6 is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate. this includes: · patients who are not adequately controlled with inhaled corticosteroid therapy and ?as needed? inhaled short-acting beta-2 adrenoceptor agonists. · patients who are already adequately controlled on regular separate long acting beta-agonist and inhaled corticosteroid therapies.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - palivizumab 100mg;   - solution for injection - 100 mg/ml - active: palivizumab 100mg   excipient: glycine histidine water for injection - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd).

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - palivizumab 50mg;   - solution for injection - 100 mg/ml - active: palivizumab 50mg   excipient: glycine histidine water for injection - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd).

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - benralizumab 30 mg/ml - solution for injection - 30 mg/ml - active: benralizumab 30 mg/ml excipient: histidine histidine hydrochloride monohydrate polysorbate 20 trehalose water for injection - fasenra is indicated as add-on therapy in patients aged 12 years and over with severe eosinophilic asthma (blood eosinophil count nlt 300 cells/µl or nlt 150 cells/µl if on oral corticosteroid treatment).